Tumor necrosis factor-alpha inhibitors and acne fulminans: Friend or foe?

Pediatr Dermatol. 2023 Jul-Aug;40(4):678-680. doi: 10.1111/pde.15226. Epub 2022 Dec 27.

Abstract

Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)-alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome-like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second-line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti-TNF alpha therapy.

Keywords: Crohn disease; TNF-alpha; acne fulminans; adalimumab; adverse reaction; paradoxical; tofacitinib.

Publication types

  • Case Reports

MeSH terms

  • Acne Vulgaris* / drug therapy
  • Adalimumab / adverse effects
  • Humans
  • Immunologic Factors / therapeutic use
  • Skin / pathology
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Tumor Necrosis Factor-alpha*

Substances

  • Tumor Necrosis Factor-alpha
  • Tumor Necrosis Factor Inhibitors
  • Adalimumab
  • Immunologic Factors